Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its older drug Pluvicto.
Data from a 101-patient study showed that 52.5% of those previously treated with Pluvicto saw levels of prostate-specific antigen, or PSA, fall by at least half when treated with the actinium-based drug. Elevated PSA level is a common marker for prostate cancer.